AKT1 and nonpapillary renal cell carcinoma: Recently, a ccRCC proteomic study reported that the PI3K/AKT/mTOR pathway was the resistance mechanism of sunitinib treatment in ccRCC patients, and the Warburg effect derived from VHL mutations can further enhance TKI resistance in ccRCC [9].